Poor
Poorly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely exceed or misstate the published labeling. Most insomnia- and sleep-related statements cited are not supported by the provided label sections (6.1, 2.1, 2.2, 5.1). A small portion of the evaluation mislabels label content as 'supported' or 'present.' Overall alignment is poor due to extensive unsupported and potentially misleading sleep-related claims.
Category Scores
Accurate Statements
Unsupported Statements
Cymbalta (duloxetine), an SNRI antidepressant, lists insomnia as a common side effect.
Not supported by the provided label excerpt; the label sections shown do not explicitly list insomnia as a common adverse event.
Clinical trials and post-marketing data show it affects 10-14% of patients, often in the first weeks of treatment as the body adjusts.
Not supported by the provided label excerpt; no numeric insomnia/adverse-event rates are given in the visible sections.
Insomnia occurs in 10% of patients on 60 mg daily for major depressive disorder.
Not supported by the provided label excerpt; no dose-specific insomnia frequency is shown.
Insomnia occurs in 14% for generalized anxiety disorder.
Not supported by the provided label excerpt; no disorder-specific insomnia frequency is shown.
Up to 22% at higher doses (120 mg).
Not supported by the provided label excerpt; no higher-dose insomnia frequency data is shown.
These rates exceed placebo (by 4-10%).
Not supported by the provided label excerpt; no comparative rates are shown.
Sleep issues typically improve after 1-2 weeks.
Not supported by the provided label excerpt; no time-to-improvement data is shown.
2-5% discontinue due to persistent problems.
Not supported by the provided label excerpt; no discontinuation-rate data for insomnia is shown.
Duloxetine boosts serotonin and norepinephrine, which can overstimulate the brain initially, delaying sleep onset or causing fragmented rest.
Not supported by the provided label excerpt; no mechanism-specific sleep impact is described in the visible sections.
Unlike SSRIs, its norepinephrine effect heightens alertness.
Not supported by the provided label excerpt; no comparative pharmacology statements are shown in the visible sections.
Evening dosing may worsen this; morning use often helps.
Not supported by the provided label excerpt; no dosing-time effects are described in the visible sections.
User reviews on Drugs.com (average 6.2/10 rating) frequently mention insomnia: 'First week was rough—wide awake at night' or 'Switched to mornings, better now.'
Not supported by the provided label excerpt; consumer-review content is not part of the label.
About 15% rate sleep disruption as a top complaint.
Not supported by the provided label excerpt; no such frequency data is shown.
Some experience vivid dreams or night sweats alongside.
Not supported by the provided label excerpt; no description of such sleep phenomena is shown.
Most cases resolve within 2-4 weeks.
Not supported by the provided label excerpt; no time-to-resolution data is shown.
If it persists beyond a month, worsens depression, or includes severe fatigue/daytime sleepiness, consult a doctor—dose adjustment, switching meds, or adding sleep aids like trazodone may be needed.
Not supported by the provided label excerpt; no such guidance is shown.
Abrupt stops can trigger withdrawal insomnia.
Not supported by the provided label excerpt; no withdrawal-insomnia guidance is shown.
Take in the morning with food.
Not supported by the provided label excerpt; label allows with or without meals, not specifically 'morning with food'.
Avoid caffeine after noon.
Not supported by the provided label excerpt; no caffeine guidance is shown.
Practice sleep hygiene: consistent bedtime, no screens.
Not supported by the provided label excerpt; no sleep-hygiene guidance is shown.
Track symptoms; providers often pair with low-dose sedatives short-term.
Not supported by the provided label excerpt; no sleep-pharmacotherapy guidance is shown.
Do not stop suddenly—taper under guidance to avoid rebound effects.
Not supported by the provided label excerpt; no taper guidance is shown in 2.1.
Cymbalta | 10-14% | Stimulating early on
Not supported by the provided label excerpt; no such frequency data is shown.
Zoloft (sertraline) | 20-25% | Higher initial risk
Not supported by the provided label excerpt; no sertraline comparison data is shown.
Prozac (fluoxetine) | 10-19% | Long half-life prolongs issues
Not supported by the provided label excerpt; no fluoxetine data is shown.
Remeron (mirtazapine) | <5% | Often improves sleep
Not supported by the provided label excerpt; no comparisons to other agents are shown.
Wellbutrin (bupropion) | 5-10% | Less sedating alternative
Not supported by the provided label excerpt; no such data is shown.
Pre-existing insomnia raises risk.
Not supported by the provided label excerpt; no risk modifiers are shown in the visible sections.
Rule out unrelated causes like anxiety rebound, thyroid issues, or sleep apnea via sleep study.
Not supported by the provided label excerpt; diagnostic guidance is not shown in the accessible sections.
FDA warns of suicidality risk in young adults if sleep loss fuels mood dips.
Not supported by the provided label excerpt; while suicidality warnings exist (5.1), the sleep-loss–specific framing is not presented in the accessible sections.
Contradictions
Important Omissions
The label excerpt provided lacks explicit insomnia-related adverse event rates and sleep-specific information; it also lacks detailed GAD dosage information (2.3) and explicit 2.2 MDD dose ranges in the visible text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Misalignment largely stems from extrapolated sleep-related claims not supported by the label. No direct, label-supported acute patient safety risks identified in the evaluation beyond standard labeling content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Most insomnia- and sleep-related claims are not supported by the provided label; some statements misinterpret or extrapolate from the label content.
Suggested Improvement
Limit claims to information explicitly present in the label (e.g., confirmed adverse reactions, dosing ranges in 2.2, administration instructions in 2.1, 5.1 suicidality warnings). Remove references to non-labeled data (consumer reviews, non-labeled rates, non-labeled drug comparisons) and avoid sleep-hygiene or concomitant-sleep-aid recommendations unless supported by the label. Provide clear, label-backed statements about indications, dosage, and safety.